Research & Development

Goldfinch Bio raises $100m to develop therapies for kidney diseases

Goldfinch Bio has raised $100m in a Series B funding round for the discovery and development of precision drugs for the treatment of kidney diseases.

Sanofi, Translate Bio expand mRNA vaccine partnership in $2.3bn worth deal

Sanofi Pasteur has signed a fresh deal potentially worth up to $2.32bn with US-based Translate Bio to expand an existing partnership of developing vaccines for infectious diseases by using the latter's messenger RNA technology (mRNA technology).

Frontier Scientific, Renibus Therapuetics to develop Covid-19 therapeutic

Frontier Scientific, a world leader in porphyrin chemistry and chemical building blocks for drug discovery and material science research, announced their collaboration with Renibus Therapuetics to develop a therapeutic for Covid-19.

Gilead Sciences to buy 49.9% stake in Pionyr Immunotherapeutics for $275m

US-based biopharmaceutical company Gilead Sciences has agreed to acquire 49.9% equity stake in Pionyr Immunotherapeutics for $275m.

Elemental Packaging

After transferring the media slurry into the open column, the piston is quickly mounted in a way that avoids air entry, and the column is sealed.

Interdisciplinary consortium receives grant to develop next-generation cell-based cancer vaccines

Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers. Access to these promising therapies is limited by the high costs of manufacturing at centralized locations. Saint-Gobain Life Sciences, Kanyr Pharma Inc., the RI-MUHC and McGill University have formed a new interdisciplinary consortium to make this technology more accessible. In this project, dendritic cell cancer vaccines will be generated in Saint-Gobain’s VueLife® “C” Series FEP bags.

IDEAYA and GSK announce a broad partnership in Synthetic Lethality

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology.  

Takeda, Neurocrine sign $2bn deal on potential therapies for psychiatric disorders

Takeda Pharmaceutical has entered into a more than $2bn worth deal with Neurocrine Biosciences to develop potential therapies for psychiatric disorders.

Cannabinoid Purification and Scale-Up on Hipersep^® Pilot

For the outstanding efficiency and scalability, high-performance liquid chromatography (HPLC) has been widely used for purification of high-quality APIs and intermediates in the pharmaceutical industry.